Verona Pharma plc (NASDAQ:VRNA) CFO Sells $64,680.00 in Stock

Verona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn sold 12,936 shares of the stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $5.00, for a total value of $64,680.00. Following the sale, the chief financial officer now owns 14,276,000 shares in the company, valued at approximately $71,380,000. This represents a 0.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Verona Pharma Trading Down 1.3 %

VRNA traded down $0.52 during trading on Monday, reaching $39.11. The company had a trading volume of 621,587 shares, compared to its average volume of 936,193. The company has a quick ratio of 12.88, a current ratio of 13.03 and a debt-to-equity ratio of 0.93. Verona Pharma plc has a 52 week low of $11.39 and a 52 week high of $40.76. The stock has a market cap of $3.13 billion, a P/E ratio of -20.37 and a beta of 0.46. The business has a 50 day simple moving average of $34.85 and a 200-day simple moving average of $25.61.

Verona Pharma (NASDAQ:VRNA) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.12). The company had revenue of $5.62 million during the quarter, compared to the consensus estimate of $2.31 million. During the same period in the prior year, the firm posted ($0.18) EPS. On average, equities analysts anticipate that Verona Pharma plc will post -2.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on VRNA shares. Wells Fargo & Company lifted their price objective on Verona Pharma from $50.00 to $64.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. HC Wainwright boosted their price target on Verona Pharma from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Canaccord Genuity Group boosted their target price on shares of Verona Pharma from $37.00 to $44.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Finally, Truist Financial increased their price target on shares of Verona Pharma from $38.00 to $44.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $43.83.

Institutional Investors Weigh In On Verona Pharma

Several hedge funds have recently made changes to their positions in the company. CWM LLC purchased a new stake in shares of Verona Pharma in the 2nd quarter worth approximately $29,000. EMC Capital Management bought a new position in Verona Pharma in the second quarter worth approximately $38,000. GAMMA Investing LLC lifted its holdings in Verona Pharma by 70.6% during the third quarter. GAMMA Investing LLC now owns 1,336 shares of the company’s stock worth $38,000 after buying an additional 553 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in Verona Pharma by 25.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock valued at $75,000 after acquiring an additional 529 shares in the last quarter. Finally, Legato Capital Management LLC bought a new position in shares of Verona Pharma in the 2nd quarter worth $154,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.